Argus Upgrades Novartis to Buy, Citing Attractive Entry Point
Argus has upgraded Novartis AG (NYSE: NVS) from Hold to Buy and established a price target of $180. The upgrade signals renewed confidence in the Swiss pharmaceutical giant, with the analyst firm pointing to what it views as an attractive entry point for investors at current price levels.
Why the Rating Changed
Argus’s decision to upgrade Novartis centers on valuation. The firm identified the stock’s current trading level as an appealing entry point for new and existing investors, suggesting that shares may be undervalued relative to the company’s fundamentals and growth trajectory.
Several broader factors appear to support the timing of this upgrade:
- Attractive valuation relative to pipeline potential: Recent coverage from Seeking Alpha noted that Novartis is advancing its immunology and oncology plans even as a “valuation gap persists.” The company recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for remibrutinib, a targeted treatment candidate for chronic spontaneous urticaria. This regulatory progress strengthens the company’s near-term commercial outlook in immunology.
- Unusual options activity suggesting bullish sentiment: Around the time of the upgrade, Novartis saw a dramatic spike in call options activity, with traders purchasing 38,221 call options in a single session — a 1,673% increase compared to the average daily volume of 2,156 call options. This surge in bullish positioning suggests that institutional and sophisticated investors may share Argus’s constructive view on the stock.
- Quantitative model support: Novartis was also highlighted as a stock pick alongside Costco and Devon Energy in a quantitative investing model designed to identify opportunities during volatile market conditions, further reinforcing the case that the stock screens well on a data-driven basis.
It is worth noting that not all institutional investors have been adding to their positions. Banco Santander reduced its Novartis stake by 51.4% during the third quarter, bringing its holdings down to 30,286 shares. While this represents a notable reduction, institutional portfolio adjustments can reflect a variety of factors unrelated to a stock’s fundamental outlook.
Novartis Dividend Profile
For income-focused investors, Novartis continues to offer a meaningful dividend. Key details include:
- Annual Dividend: $4.77 per share
- Dividend Yield: 2.95%
- Most Recent Ex-Dividend Date: March 10, 2026
At a yield of nearly 3%, Novartis provides a solid income component that complements the capital appreciation potential implied by Argus’s $180 price target. The company has a long history of returning capital to shareholders, making it a stock frequently tracked by dividend investors. With the new Buy rating and established price target, Argus is effectively signaling that investors can collect a competitive yield while waiting for the valuation gap to close.
Looking Ahead
With regulatory momentum building around key pipeline assets like remibrutinib and a valuation that Argus considers attractive, Novartis appears well-positioned within the large-cap pharmaceutical space. The $180 price target suggests meaningful upside potential from current levels, and the company’s steady dividend adds an additional layer of total return for patient investors.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.